**COMPOSITION:**

Nifedipine - 5 Capsules  
Each capsule contains Nifedipine IP 5 mg.

Nifedipine - 10 Capsules  
Each capsule contains Nifedipine IP 10 mg.

Nifedipine RETARD Tablets  
Each film-coated slow-release tablet contains Nifedipine IP 20 mg.

**PHARMACOLOGY:**

**Pharmacodynamics:**

Nifedipine is a specific and potent calcium antagonist with mainly vascular effects.

As a specific and potent calcium antagonist, the main action of nifedipine is to relax arterial smooth muscle both in the coronary and peripheral circulation.

In angina pectoris, nifedipine capsules relax peripheral arteries so reducing the load on the left ventricle. Additionally, nifedipine dilates submaximally both clear and pre-stenotic, stenotic and post-stenotic coronary arteries, thus protecting the heart against coronary artery spasm and improving perfusion to the ischaemic myocardium.

Nifedipine reduce the frequency of painful attacks and ischaemic ECG changes, irrespective of the relative contribution from coronary artery spasm or atherosclerosis.

Nifedipine causes a reduction in blood pressure such that the percentage lowering is directly related to its initial level. In normotensive individuals, nifedipine has little or no effect on blood pressure.

**Pharmacokinetics:**

Nifedipine  
Greater than 90% of a single oral or sub-lingual dose of nifedipine is absorbed.

Radioactivity is detected in the serum 20 minutes after an oral dose and 10 minutes after a sub-lingual dose. Maximal equivalent serum concentrations are achieved 1-2 hours after enteral administration and these correspond to the equivalent concentrations over the same time period after intravenous administration (the drug is almost completely absorbed).

After enteral or intravenous doses, 70-80% of activity is eliminated (primarily as metabolites) via the urine. Remaining excretion is via the faeces.

After 24 hours, 90% of the administered dose is eliminated.

Protein binding of nifedipine exceeds 90% in human serum.

Nifedipine RETARD  
Absorption and distribution  
Nifedipine is absorbed almost completely from the gastro-intestinal tract regardless of the oral formulation used. Protein binding of nifedipine exceeds 90% in human serum.

Metabolism and elimination  
Nifedipine undergoes extensive metabolism in the liver to inactive metabolites, with less than 1% of the parent drug appearing unchanged in the urine. The rate of absorption determines the drug’s apparent elimination. The apparent elimination phase half-life for Nifedipine RETARD 20 mg tablets has been estimated as 2.2 - 2.4 ± 0.8 hours.
Nifedipine

tablets film-coated, tablets film-coated

INDICATIONS:

Nifedipine is indicated in the prophylaxis and treatment of vasospastic angina and chronic stable angina, and Raynaud’s phenomenon.

Nifedipine RETARD is indicated for the treatment of hypertension. It may be used in combination with other antihypertensive agents. Nifedipine RETARD is also indicated in prophylaxis of chronic stable angina pectoris.

DOSAGE AND ADMINISTRATION:

Nifedipine capsules should be swallowed with a little fluid, during or after food. The dosage should be established by titration. Excessive doses can result in hypotension. Dose range for the treatment of angina is 30 mg to 80 mg/day. The starting dose is 5 mg thrice daily and this is gradually increased over 7 to 14 days as required. For rapid relief in angina, the capsule is bitten and the contents retained in the mouth. Doses more than 180 mg/day is not recommended.

Nifedipine RETARD administered twice daily provides a 24-hour control of raised blood pressure in hypertension as well as a 24-hour control of ischemia in angina pectoris. These tablets should be swallowed whole and should not be bitten or divided.

CONTRAINDICATIONS:

Aortic stenosis, unstable angina, acute angina, acute myocardial infarction, secondary prevention of myocardial infarction and hypersensitivity to the drug or other dihydropyridines.

Note: This product information is intended only for residents of the India. Taj Pharmaceuticals Limited, medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world. The Price of the drugs indicated above may not match the actual price at which they are sold. Prices can change depending on many factors, including local taxes. These are only approximate indicative prices of the drug. The products discussed herein may have different product labeling in different countries. The product information provided in this site is intended only for the residents of India.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited).

Further Details Please Visit: www.tajpharma.com
This document includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the fact that they do not only relate to historical or current events. Forward-looking statements often use words such as “anticipate”, “target”, “expect”, “estimate”, “intend”, “expected”, “plan”, “goal” believe”, or other words of similar meaning. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances, a number of which are beyond Company’s control. As a result, actual future results may differ materially from the plans, goals and expectations set out in these forward-looking statements. Any forward-looking statements made by or on behalf of the Company speak only as at the date of this announcement. Save as required by any applicable laws or regulations, the Company undertakes no obligation publicly to release the results of any revisions to any forward-looking statements in this document that may occur due to any change in its expectations or to reflect events or circumstances after the date of this document. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States. This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as “relevant persons”). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.
About Taj Pharmaceutical Limited

Taj Pharmaceuticals Limited is a pharmaceutical company founded and based in India. The company manufactures pharmaceutical formulations and API for India and other countries of the world. The company was established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai pharmaxil and Chemixil association the company manufacturers and exports to countries like Albania, Argentina, Austria, Chile and Iraq. In 1995 pharmaceuticals wing only has a schedule M certification for pharmaceuticals products manufacturing in India. Taj Pharmaceuticals established its manufacturing unit in Gujarat because of government policies in 1999 with WHO / GMP licence. The company in 2003 revived all the old manufacturing units and approached the FDA Gujarat for 4000 new pharmaceuticals drug permissions for the first time in India.

According to the Indian Trade Mark the company owns about 450 brands and 4600 generic manufacturing permissions in India. According to the export data analysis the company was the largest exporter of generic medicines to the Europe and Middle East countries.

www.tajpharma.com

The company medicines are present in France, Georgia, Egypt and CIF countries.
Further Details Please Visit: www.tajpharma.com